|
Market Closed -
Nasdaq
16:00:00 2026-09-08 EDT
|
5-day change | 1st Jan Change | ||
| 9.065 USD | -8.99% |
|
-8.62% | +16.22% |
| 09-08 | Pharvaris' genetic disorder drug meets main goal in late-stage trial | RE |
| 08-25 | BioCryst Pharmaceuticals Announces Approval Of ORLADEYO For Pediatric HAE Patients In Japan | CI |
Main competitors
| Change | 5-day change | 1-month change | 3-month change | YTD change | 1-year change | 3-year change | 5-year change | 10-year change | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | -8.99% | -8.62% | -3.36% | +7.53% | +16.22% | +10.68% | +28.04% | -39.41% | +99.67% | 2.32B | |
| +2.02% | +1.26% | +0.99% | +62.86% | +72.50% | +41.37% | +105.18% | +11.75% | - | 69.19B | |
| -0.12% | -4.09% | +12.62% | +13.96% | +20.51% | +32.32% | +75.68% | +205.23% | +5,877.85% | 62.97B | |
| -1.11% | +2.78% | -4.74% | +32.62% | -28.24% | -14.86% | +375.59% | +349.08% | +796.55% | 27.27B | |
| -4.92% | -3.22% | +5.33% | +15.39% | +3.63% | -3.90% | -17.87% | -70.66% | - | 24.78B | |
| -0.97% | -0.81% | +5.90% | +63.13% | +55.34% | +29.69% | +14.38% | -59.23% | - | 25.8B | |
| +0.23% | +0.84% | +8.30% | +34.39% | +6.81% | +24.50% | -17.84% | -25.16% | +110.40% | 20.11B | |
| +6.04% | +7.25% | +13.31% | +68.31% | +231.60% | +233.25% | +383.12% | +1,838.96% | +899.74% | 18.47B | |
| -1.19% | -2.23% | -8.80% | +24.42% | +22.90% | -7.93% | +517.16% | - | - | 14.88B | |
| -2.27% | +1.37% | +6.66% | +11.46% | +31.58% | +53.01% | +160.83% | +190.09% | +366.96% | 14.29B | |
| -1.85% | +22.03% | +23.78% | +22.47% | -1.20% | -11.13% | +1,022.08% | +167.08% | +178.26% | 13.79B | |
| -1.28% | -0.84% | +4.73% | +14.31% | -8.27% | +17.71% | +171.73% | +581.76% | +4,751.59% | 12.34B | |
| -1.42% | +2.86% | -2.90% | +15.23% | +28.20% | +213.25% | +184.65% | +29.25% | +1,012.55% | 12.02B | |
| -1.04% | +8.37% | -6.26% | +6.37% | -15.80% | -32.08% | +158.21% | +122.57% | - | 11.3B | |
| +3.62% | +5.53% | -1.84% | +10.97% | +18.59% | +44.65% | +108.96% | +142.13% | +697.35% | 10.48B | |
| -1.31% | -0.74% | +3.94% | +30.28% | +30.82% | +86.24% | +19.10% | +139.05% | - | 8.98B | |
| +2.60% | +5.34% | +8.51% | +15.62% | +318.69% | +243.98% | +542.64% | -19.36% | - | 8.79B | |
| -1.28% | -3.14% | -9.14% | +11.19% | +6.94% | -26.25% | +103.97% | -27.36% | - | 8.54B | |
| +2.03% | +2.59% | -13.46% | +26.10% | +177.14% | +445.94% | +548.50% | -50.66% | -50.46% | 8.01B | |
| -0.39% | +23.07% | +18.28% | +38.12% | +20.56% | +185.66% | +512.03% | - | - | 7.77B | |
| Average | -0.78% | +3.42% | +3.09% | +26.24% | +50.43% | +78.31% | +249.81% | +193.62% | +1,340.04% | 19.1B | |
| Weighted average by Cap. | -0.16% | +1.99% | +4.49% | +32.69% | +45.15% | +55.14% | +195.09% | +192.56% | +2,456.47% |
- Stock Market
- Stocks
- BCRX Stock
- Sector BioCryst Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
